

***Fiscal Year 2021 Neurofibromatosis Research Program (NFRP)  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Clinical Trial Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> W81XWH-21-NFRP-CTA</p>	<p>Must be <i>at or above</i> the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> <li>• Supports research with the potential to have a major impact on the treatment or management of NF.</li> <li>• Funds phase 0, 1, or 2 clinical trials relevant to NF and/or schwannomatosis. Combinations of phases are permitted.</li> <li>• <b><i>Must support a clinical trial and may not be used for preclinical research studies.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum period of performance is <b>4</b> years.</li> <li>• The maximum allowable funding for the entire period of performance is <b>\$800,000</b> in direct costs (<b>\$1,000,000</b> in direct costs if requesting the Qualified Organizational Collaboration Option).</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> July 8, 2021 5:00 p.m. Eastern time (ET)</p> <p><b>Application:</b> July 22, 2021 11:59 p.m. ET</p>
<p><b>Early Investigator Research Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> W81XWH-21-NFRP-EIRA</p>	<p>The investigator must:</p> <ul style="list-style-type: none"> <li>• Be involved in a postdoctoral training or medical residency program; and</li> <li>• Possess at least 1 and up to 4 years of continuous postdoctoral research experience by application submission deadline; and</li> </ul> <p>Possess a <b>doctoral</b> degree (i.e., Ph.D., M.D./Ph.D., D.O./Ph.D.) or a <b>clinical doctoral</b> degree (i.e., M.D./D.O. or Ph.D. in a clinical discipline) from an accredited organization or program.</p>	<ul style="list-style-type: none"> <li>• Supports NF-focused research opportunities for individuals in the early stages of their careers.</li> <li>• Investigators must have a <b>designated mentor</b> who is an experienced NF researcher.</li> </ul>	<ul style="list-style-type: none"> <li>• The maximum period of performance is <b>2</b> years.</li> <li>• The maximum allowable funding for the entire period of performance is <b>\$200,000</b> in direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> </ul>	<p><b>Pre-application (Letter of Intent):</b> July 8, 2021 5:00 p.m. ET</p> <p><b>Confidential Letters of Recommendation:</b> July 27, 2021 5:00 p.m. ET</p> <p><b>Application:</b> July 22, 2021 11:59 p.m. ET</p>

***Fiscal Year 2021 Neurofibromatosis Research Program (NFRP)  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Exploration – Hypothesis Development Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> W81XWH-21-NFRP-EHDA</p>	<p>Investigators at all academic levels (or equivalent).</p>	<ul style="list-style-type: none"> <li>• Supports the initial exploration of innovative, high-risk, high-gain concepts and potentially groundbreaking concepts in NF research.</li> <li>• <i>Preliminary and/or published data are encouraged but not required.</i></li> <li>• Clinical trials are not allowed.</li> </ul>	<ul style="list-style-type: none"> <li>• The maximum period of performance is <b>2</b> years.</li> <li>• The maximum allowable funding for the entire period of performance is <b>\$100,000</b> in direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> July 8, 2021 5:00 p.m. Eastern time (ET)</p> <p><b>Application:</b> July 22, 2021 11:59 p.m. ET</p>
<p><b>Investigator-Initiated Research Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> W81XWH-20-NFRP-IIRA</p>	<ul style="list-style-type: none"> <li>• Must be an investigator <i>at or above</i> the level of Assistant Professor (or equivalent) who plans to commit <i>at least a 10% level of effort</i> for each budget period for the entirety of the award.</li> </ul>	<ul style="list-style-type: none"> <li>• Supports highly rigorous, high-impact research with the potential to make an important contribution to NF research and/or patient care.</li> <li>• <i>Preliminary and/or published data relevant to NF are required.</i></li> <li>• <b>Optional Features:</b> Applications meeting criteria identified in the program announcement may apply for a higher level of funding for the following options: Qualified Collaborator and/or NF Open Science Initiative (NF-OSI).</li> </ul>	<ul style="list-style-type: none"> <li>• The maximum period of performance is <b>3</b> years.</li> <li>• The maximum allowable funding for the entire period of performance is <b>\$525,000</b> in direct costs.</li> <li>• The maximum allowable funding for applications including <i>either</i> the Optional Qualified Collaborator <i>or</i> the NF-OSI Option is <b>\$575,000</b> in direct costs.</li> <li>• The maximum allowable funding for applications including <i>both</i> the Optional Qualified Collaborator Option and the NF-OSI Option is <b>\$625,000</b> in direct costs.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> July 8, 2021 5:00 p.m. Eastern time (ET)</p> <p><b>Application:</b> July 22, 2021 11:59 p.m. ET</p>

***Fiscal Year 2021 Neurofibromatosis Research Program (NFRP)  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
		<ul style="list-style-type: none"> <li>Clinical trials are not allowed.</li> </ul>	costs. <ul style="list-style-type: none"> <li>Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul>	
<p><b>Synergistic Idea Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>Program Announcement</li> <li>General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> W81XWH-21-NFRP-SIA</p>	<p>Must be an investigator <i>at or above</i> the level of Assistant Professor (or equivalent) who plans to commit <i>at least a 10% level of effort</i> for each budget period throughout the entirety of the award.</p>	<ul style="list-style-type: none"> <li>Supports new ideas that represent synergistic approaches involving <b>two or three</b> Principal Investigators (PIs) (Initiating PIs and PI[s]) to address a central problem or question in NF research.</li> <li><i>Preliminary and/or published data are required.</i></li> <li>Clinical trials are not allowed.</li> </ul>	<ul style="list-style-type: none"> <li>The maximum period of performance is <b>3</b> years.</li> <li>The maximum allowable funding for the entire period of performance is <b>\$200,000,000</b> in direct costs.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> July 8, 2021 5:00 p.m. Eastern time (ET)</p> <p><b>Application:</b> July 22, 2021 11:59 p.m. ET</p>
<p><b>Clinical Consortium Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>Program Announcement</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> W81XWH-21-NFRP-CTCA</p>	<p>The Operations Center PI must be an independent investigator at or above the level of Associate Professor (or equivalent) with experience in developing and running large scale initiatives such as clinical trials or consortia. Additional criteria are described in the announcement.</p>	<ul style="list-style-type: none"> <li>The NFRP Clinical Trial Consortium requires collaboration of multiple organizations and individuals for the purpose of rapidly executing clinical trials. Therefore, the offeror must have a demonstrated history of large scale collaborative research.</li> <li>This award will be issued as a Research Other</li> </ul>	<ul style="list-style-type: none"> <li>The maximum period of performance is 10 years.</li> <li>The maximum allowable funding for the entire period of performance is \$25,000,000 in total costs.</li> <li>Indirect costs may be proposed in accordance with your institution's negotiated rate agreement.</li> </ul> <p><i>Note that only \$5M total funding (direct and indirect costs) allocated for this award</i></p>	<p><b>Pre-application (Pre-Proposal):</b> September 17, 2021 5:00 p.m. Eastern time (ET)</p> <p>Invitation to Submit an Application: September 24, 2021</p> <p><b>Application:</b> October 29, 2021 11:59 p.m. ET</p>

***Fiscal Year 2021 Neurofibromatosis Research Program (NFRP)  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
		<p>Transaction Agreement (rOTA).</p> <ul style="list-style-type: none"> <li>The objectives of the rOTA are the conception, design, development, and conduct of collaborative Phase I and II clinical evaluations of promising therapeutic agents for the management or treatment of NF1, NF2, and schwannomatosis.</li> </ul>	<p><i>will be from the FY21 NFRP budget; the balance is contingent upon receipt of sufficient congressional appropriations to the NFRP in future years</i></p>	